A number of chemokine/chemokine receptor antagonists are being developed for tumour immunotherapy and it remains to be seen whether blocking of CCR6/CCL20 would impact on immunosuppression in squamous cell cancers [29], [30]. The gene discussed is CCR6; the disease is neoplasm.